The Safety and Tolerability of Nebivolol in Hypertensive Patients with Coronary Artery Disease and Left Ventricular Ejection Fraction ≥ 40%: A Population-Based Cohort Study (Nebivolol-TR Study).

Autor:	Altın C; Department of Cardiology, Başkent University Faculty of Medicine, İzmir, Turkey., Okyay K; Department of Cardiology, Başkent University Faculty of Medicine, Ankara, Turkey., Kış M; Department of Cardiology, Silopi State Hospital, Şırnak, Turkey., Eren H; Department of Cardiology, Elbistan State Hospital, Kahramanmaraş, Turkey., Bekar L; Department of Cardiology, Hitit University Faculty of Medicine, Çorum, Turkey., Doğan Y; Department of Cardiology, Kayseri City Hospital, Kayseri, Turkey., Aydın G; Department of Cardiology, Balıkesir City Hospital, Balıkesir, Turkey., Güzel T; Department of Cardiology, Akhisar State Hospital, Manisa, Turkey., Harbalıoğlu H; Department of Cardiology, Düzce Atatürk State Hospital, Düzce, Turkey., Tanık VO; Department of Cardiology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey., Çerşit S; Department of Cardiology, Kartal Koşuyolu Training and Research Hospital, İstanbul, Turkey., Çakmak Karaaslan Ö; Department of Cardiology, Ankara City Hospital, Ankara, Turkey., Çekici Y; Department of Cardiology, Mehmet Akif İnan Training and Research Hospital, Şanlıurfa, Turkey., Böyük F; Department of Cardiology, Yedikule Training and Research Hospital, İstanbul, Turkey., Çoner A; Department of Cardiology, Başkent University Faculty of Medicine, Alanya, Turkey., Kocabaş U; Department of Cardiology, Başkent University Faculty of Medicine, İzmir, Turkey., Yenerçağ M; Department of Cardiology, Samsun Training and Research Hospital, Samsun, Turkey., Çalışkan S; Department of Cardiology, Bahçelievler State Hospital, İstanbul, Turkey., Er F; Department of Cardiology Ağrı State Hospital, Ağrı, Turkey., Sinan ÜY; Department of Cardiology, İstanbul University Cerrahpaşa Institution of Cardiology, İstanbul, Turkey., Ulus T; Department of Cardiology, Osmangazi University Faculty of Medicine, Eskişehir, Turkey., Gül S; Department of Cardiology, Samsun Training and Research Hospital, Samsun, Turkey., Öz A; Department of Cardiology, İstanbul Training and Research Hospital, İstanbul, Turkey., Candemir A; Department of Cardiology, Ege University Faculty of Medicine, İzmir, Turkey., Çetinarslan Ö; Department of Cardiology Malazgirt State Hospital, Muş, Turkey., Yüce Eİ; Department of Cardiology Kelkit State Hospital, Gümüşhane, Turkey., Tanrıverdi Z; Department of Cardiology, Harran University Faculty of Medicine, Şanlıurfa, Turkey., Taşcanov MB; Department of Cardiology, Harran University Faculty of Medicine, Şanlıurfa, Turkey., Yeni M; Department of Cardiology, Isparta City Hospital, Isparta, Turkey., Özbay B; Department of Cardiology, İstanbul Çam and Sakura State Hospital, İstanbul, Turkey., Öztürk Ö; Department of Cardiology Gazi Yaşargil State Hospital, Diyarbakır, Turkey., Bedir Ö; Department of Cardiology, Cizre State Hospital, Şırnak, Turkey., Yılmaz MM; Department of Cardiology, Hitit University Faculty of Medicine, Çorum, Turkey., Tekindal MA; Department of Biostatistic, Katip Çelebi University Faculty of Medicine, İzmir, Turkey., Zoghi M; Department of Cardiology, Ege University Faculty of Medicine, İzmir, Turkey.
Jazyk:	angličtina
Zdroj:	Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir [Turk Kardiyol Dern Ars] 2022 Dec; Vol. 50 (8), pp. 568-575.
DOI:	10.5543/tkda.2022.21237
Abstrakt:	Background: This study aimed to assess the safety and tolerability of nebivolol in hypertensive patients with coronary artery disease and left ventricular ejection fraction ≥ 40% in a Turkish cohort. Methods: A total of 1015 hypertensive patients and coronary artery disease with left ventricular ejection fraction ≥ 40% were analyzed from 29 different centers in Turkey. Primary outcomes were the mean change in blood pressure and heart rate. Secondary outcomes were to assess the rate of reaching targeted blood pressure (<130/80 mmHg) and heart rate (<60 bpm) and the changes in the clinical symptoms (angina and dyspnea). Adverse clinical events and clinical outcomes including cardiovascular mortality, cardiovascular hospital admissions, or acute cardiac event were recorded. Results: The mean age of the study population was 60.3 ± 11.5 years (male: 54.2%). During a mean follow-up of 6 months, the mean change in blood pressure was -11.2 ± 23.5/-5.1 ± 13.5 mmHg, and the resting heart rate was -12.1 ± 3.5 bpm. Target blood pressure and heart rate were achieved in 76.5% and 37.7% of patients. Angina and functional classifications were improved by at least 1 or more categories in 31% and 23.2% of patients. No serious adverse events related to nebivolol were reported. The most common cardiovascular side effect was symptomatic hypotension (4.2%). The discontinuation rate was 1.7%. Cardiovascular hospital admission rate was 5% and hospitalization due to heart failure was 1.9% during 6 months' follow-up. Cardiovascular mortality rate was 0.1%. Conclusion: Nebivolol was well tolerated and safe for achieving blood pressure and heart rate control in hypertensive patients with coronary artery disease and heart failure with preserved or mildly reduced ejection fraction.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu